# Study Guide: Global Strategy for Asthma Management and Prevention (2026 Update)

This study guide provides a synthesized overview of the 2026 GINA (Global Initiative for Asthma) Strategy Report. It covers the definition, diagnosis, assessment, and management of asthma across various age groups, incorporating the latest clinical evidence and updated treatment flowcharts.

---

## Section 1: Key Concepts and Definitions

### 1.1 Definition and Nature of Asthma
Asthma is a **heterogeneous disease** typically characterized by **chronic airway inflammation**. It is defined by two main components:
*   **Symptom History:** Respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough that vary over time and in intensity.
*   **Variable Expiratory Airflow:** Documented limitation in airflow that is not constant.

### 1.2 Clinical Phenotypes
Asthma presents in recognizable clusters of demographic, clinical, or pathophysiological characteristics:
*   **Allergic Asthma:** Often childhood-onset; associated with family history of allergic disease; typically responds well to inhaled corticosteroids (ICS).
*   **Non-allergic Asthma:** Sputum may be neutrophilic or paucigranulocytic; often shows a lesser short-term response to ICS.
*   **Adult-onset (Late-onset) Asthma:** More common in women; often non-allergic and may require higher ICS doses.
*   **Cough Variant Asthma:** Cough is the primary or only symptom; requires bronchial provocation testing for diagnosis if spirometry is normal.
*   **Asthma with Obesity:** Prominent respiratory symptoms with little eosinophilic inflammation.

### 1.3 Core Management Goals
The GINA strategy defines goals at both the population and individual levels:
*   **Population Level:** Prevent asthma deaths and minimize the burden on health systems and the environment.
*   **Individual Level:** 
    *   **Symptom Control:** Achieve few/no symptoms, no sleep disturbance, and unimpaired physical activity.
    *   **Risk Minimization:** Prevent exacerbations, maintain personal best lung function, and minimize medication side effects (particularly from oral corticosteroids).

---

## Section 2: Diagnosis and Assessment

### 2.1 Diagnostic Criteria for Adults and Children (6–17 years)
Diagnosis should ideally be confirmed before starting treatment. Key criteria include:

| Feature | Criteria for Adults | Criteria for Children (6–17) |
| :--- | :--- | :--- |
| **Positive Bronchodilator (BD) Responsiveness** | Increase in FEV1 >12% and >200 mL from baseline | Increase in FEV1 >12% predicted |
| **Diurnal PEF Variability** | Average daily variability >10% over 2 weeks | Average daily variability >13% over 2 weeks |
| **Response to ICS Treatment** | Increase in FEV1 >12% and >200 mL after 4 weeks | Increase in FEV1 >12% predicted after 4 weeks |
| **Bronchial Provocation** | Fall in FEV1 ≥20% (methacholine) or ≥15% (mannitol/exercise) | Fall in FEV1 ≥20% (methacholine) or >12% predicted (exercise) |

### 2.2 Type 2 Biomarkers
In patients with typical symptoms, the following biomarkers support a Type 2 asthma diagnosis but do not rule it out if levels are low:
*   **FeNO (Fractional exhaled Nitric Oxide):** >50 ppb in adults/adolescents; >35 ppb in children.
*   **Blood Eosinophils:** Levels above national/regional reference ranges.
*   **Sputum Eosinophilia:** Elevated levels in induced sputum.

### 2.3 Assessment of Asthma Control
Assessment is divided into two domains:
1.  **Symptom Control:** Evaluated via daytime symptoms, night waking, activity limitation, and reliever use frequency.
2.  **Future Risk:** Evaluated via history of exacerbations, low FEV1, high SABA use, smoking, and blood eosinophilia.

---

## Section 3: Medication and Treatment Tracks

### 3.1 Treatment Tracks for Adults and Adolescents
GINA 2026 emphasizes two distinct treatment tracks:

*   **Track 1 (Preferred):** Uses **low-dose ICS-formoterol** as the reliever. This is preferred because it reduces the risk of severe exacerbations compared to SABA relievers. It is used as "Anti-inflammatory Reliever" (AIR) therapy or "Maintenance and Reliever Therapy" (MART).
*   **Track 2 (Alternative):** Uses SABA (or ICS-SABA) as the reliever. This is recommended only if Track 1 is not possible or if the patient is stable on their current regimen.

### 3.2 2026 Updates in Management
*   **OCS Stewardship:** A high priority to reduce systemic corticosteroid exposure through optimized inhaled therapy and biologic use.
*   **Oxygen Targets:** During exacerbations, supplemental oxygen is only recommended if saturation is **<92%**. The target range for adults and children 6–11 is **92–95%**.
*   **Biologics:** New options include **depemokimab** (a long-acting anti-IL5 injected every 26 weeks) and **generic anti-IgE (omalizumab-igec)**.
*   **Environmental Impact:** GINA supports transitioning to dry-powder inhalers (DPIs) or low-carbon propellant pressurized metered-dose inhalers (pMDIs) to reduce the carbon footprint of asthma care.

---

## Section 4: Short-Answer Practice Quiz

**1. What is the pathognomonic feature of asthma-related bronchoconstriction regarding exercise?**
*Answer: Symptoms that develop or worsen after exercise and improve once the patient rests (unlike other causes of dyspnea).*

**2. Why does GINA recommend "testing before treating" whenever possible?**
*Answer: Because ICS treatment reduces the variability of symptoms and lung function, making it much more difficult to confirm the diagnosis once treatment has begun.*

**3. What are the specific oxygen saturation targets for a child under 5 years old experiencing an asthma exacerbation?**
*Answer: The target saturation is ≥92%.*

**4. Name three factors that increase the probability that respiratory symptoms are due to asthma.**
*Answer: Symptoms are worse at night or early morning; symptoms vary in intensity over time; symptoms are triggered by viral infections, exercise, or allergens.*

**5. How frequently should the new long-acting anti-IL5 biologic, depemokimab, be administered?**
*Answer: Every 26 weeks.*

**6. What is the Chronic Airways Assessment Test (CAAT)?**
*Answer: A simple, eight-item tool for comprehensive patient-centered evaluation of health status across respiratory diseases, including asthma and COPD.*

---

## Section 5: Essay Prompts for Deeper Exploration

1.  **The Evolution of Reliever Therapy:** Discuss why GINA now prefers ICS-formoterol over SABA-only relievers for adults and adolescents. Incorporate the concepts of "selective non-adherence" and the reduction of severe exacerbation risks.
2.  **Global Health Inequities in Asthma Care:** Based on the source context, analyze the challenges faced by low- and middle-income countries (LMICs) regarding asthma diagnosis and the "syndromic approach." What role does the WHO Essential Medicines List play in addressing these issues?
3.  **The Impact of Climate Change on Inhaler Technology:** Evaluate the environmental concerns regarding pMDI propellants and the strategic shift toward dry-powder inhalers (DPIs) and low-carbon alternatives. How should a clinician balance environmental priorities with patient safety?
4.  **Managing Severe Asthma Phenotypes:** Explain the "decision tree" approach to severe asthma. How do clinicians choose between biologic therapies like anti-IgE, anti-IL5, and anti-TSLP, and what role do comorbidities play in this selection?

---

## Section 6: Glossary of Important Terms

| Term | Definition |
| :--- | :--- |
| **AIR** | Anti-inflammatory Reliever (e.g., ICS-formoterol or ICS-SABA used as needed). |
| **AERD** | Aspirin-exacerbated respiratory disease. |
| **DPI** | Dry-powder inhaler. |
| **FeNO** | Fractional concentration of exhaled nitric oxide; a biomarker for Type 2 inflammation. |
| **FEV1** | Forced expiratory volume in 1 second; measured via spirometry. |
| **FVC** | Forced vital capacity; the total volume of air that can be forcibly exhaled from the lungs. |
| **ICS** | Inhaled corticosteroid; the cornerstone of asthma maintenance therapy. |
| **LABA** | Long-acting beta2-agonist (e.g., formoterol, salmeterol). |
| **MART / SMART** | Maintenance-and-Reliever Therapy; using a single ICS-formoterol inhaler for both daily maintenance and symptom relief. |
| **OCS** | Oral corticosteroid; systemic treatment usually reserved for severe exacerbations or refractory asthma. |
| **PEF** | Peak expiratory flow; the maximum speed of expiration. |
| **pMDI** | Pressurized metered-dose inhaler. |
| **PRAM** | Pediatric Respiratory Assessment Measure; a validated score for assessing exacerbation severity in children. |
| **SABA** | Short-acting beta2-agonist (e.g., salbutamol/albuterol). |
| **TSLP** | Thymic stromal lymphopoietin; a target for certain biologic therapies in severe asthma. |